Jade Biosciences Q2 net loss widens as costs rise

Jade Biosciences

10/08/2026 12:12

Overview
US biotech firm's Q2 net loss widened, missing analyst expectations
Net loss increased due to higher R&D and G&A expenses
Cash and investments rose to $461 mln after $172.5 mln public offering

Outlook
Company expects interim Phase 2 data for JADE101 in IgA nephropathy in 2027
Phase 3 JADE101 registrational trial expected to begin in first half of 2027
Company expects cash runway to extend into the fourth quarter of 2028

Result Drivers
HIGHER R&D SPENDING - Co said increased R&D expenses were due to higher costs for chemistry, manufacturing, controls, clinical activity, milestone payments, and personnel, including stock-based compensation
HIGHER G&A COSTS - Co attributed higher G&A expenses to increased personnel-related costs and stock-based compensation

Company press release: ID:nGNX8jXxMZ

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
Miss
$55.80 mln
$42.11 mln (9 Analysts)
Q2 Cash & Investments
 
$461.20 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Jade Biosciences Inc is $45.00, about 104.9% above its August 7 closing price of $21.96

Reuters Recommended Reads
Aug 7 - ANI Pharmaceuticals Q2 adjusted EPS beats on increased volume in specialty areas
Aug 7 - Rapid Micro Biosystems Q2 revenue beats; reaffirms 2026 revenue forecast
Aug 7 - bioAffinity Technologies Q2 revenue rises on CyPath Lung demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)